Shoulder Innovations, Inc.

NYSE:SI

Medical - Specialties

Healthcare
$20.65 -0.72%

-$0.13 today

Market cap
$432.04M
Beta
-1.07
P/E (TTM)
-8.4
EPS (TTM)
-$2.13
52W Low $10.92High $19.79

Volume 0.09M

Average 0.10M

SI Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Shoulder Innovations, Inc.NYSE: SI

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $3.75M rose 137.1% year over year, ahead of the +98.0% change in trailing-twelve-month research & development. Sequentially, it rose 16.7% from the prior quarter.

Context

  • Research & development amounted to 16.3% of revenue in FY2025, up 2.1 pp from a year earlier.
  • Research & development increased in 2 of the last 2 fiscal years.
  • FY2025 was the highest annual figure in the 3 fiscal years shown.

What to watch

Whether quarterly growth of +137.1% holds above the trailing-twelve-month pace of +98.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.75M+16.7% QoQ
Last fiscal yearDec 2025
$7.73M+72.2% YoY
LTMMar 2026
$9.9M+98.0% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+137.1%——
1 year+72.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
7.73M USD
Year-over-year change
+72.2%
2-year CAGR
+60.0%

Research & Development vs competitors

How SI compares with its peers on the latest reported figures

  • SI's LTM Mar 2026 research & development of $9.9M is the 10th highest of the 11 companies compared; the peer median is $24.26M.
  • Its year-over-year change of +98.0% is the 3rd highest of 11, against a peer median of +2.7%.
  • Research & development amounts to 18.4% of revenue for SI, versus a peer median of 18.1%.
SI Competitors Peer median
Research & Development for SI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$91.32M -20.8%-13.4%131.9%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$64.86M +10.1%-2.5%91.2%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$57.75M +141.5%+89.7%—
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$40.3M -12.6%+4.1%—
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$27.18M +72.6%+29.4%—
OMOutset Medical, Inc.LTM Mar 2026$21.34M -31.8%-24.3%18.1%
INGNInogen, Inc.LTM Mar 2026$20.46M +7.3%-4.0%5.8%
NNOXNano-X Imaging Ltd.LTM Dec 2025$19.24M -4.7%-10.1%147.7%
MDXHMDxHealth S.A.FY2025$10.35M -1.9%+11.1%9.6%
SIShoulder Innovations, Inc.LTM Mar 2026$9.9M +98.0%—18.4%
SNWVSANUWAVE Health, Inc.LTM Mar 2026$1.81M +151.4%+33.6%4.1%
Peer median (excluding SI) $24.26M+2.7%+0.8%18.1%

Competitors are the stored peer set for SI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue19.27M31.62M47.32M
Cost of Revenue4M7.28M11.12M
Gross Profit15.27M24.34M36.2M
Gross Margin79.2%77.0%76.5%
Research & Development3.02M4.49M7.73M
Selling, General & Admin23.11M34.51M54.77M
Operating Expenses26.13M38.99M62.5M
Depreciation & Amortization1.64M2.2M3.21M
EBITDA(10.25M)(12.11M)(37.08M)
EBITDA Margin-53.2%-38.3%-78.4%
Operating Income(10.86M)(14.65M)(26.3M)
Operating Margin-56.4%-46.3%-55.6%
Interest Income000
Interest Expense761K1.32M70K
Other Income / Expenses(1.79M)(966K)(14.06M)
Income Before Tax(12.66M)(15.62M)(40.36M)
Pre-Tax Margin-65.7%-49.4%-85.3%
Income Tax Expense000
Net Income(12.66M)(15.62M)(40.36M)
Net Margin-65.7%-49.4%-85.3%
EPS (Basic)(0.63)(0.77)(1.96)
EPS (Diluted)(0.63)(0.77)(1.96)
Weighted Avg Shares19.92M19.92M20.63M
Weighted Avg Shares (Diluted)19.92M19.92M20.63M

Shoulder Innovations, Inc.

NYSE:SI

Intrinsic Alpha fair value

Locked

Current Price

$20.65

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.